Inhibition of the transcription factor NFκB—along with other transcription factors, e.g., AP-1—leads to diminished expression of matrix-degrading proteases, like MMPs, and in consequence to reduced invasive capacity of the tumor cells. The gene discussed is NFKB1; the disease is neoplasm.